Alzheimer's Drug Discovery Foundation: 2016 Preclinical Drug Discovery RFP

The Alzheimer's Drug Discovery Foundation is accepting letters of interest that seek to fill the critical translational funding gap between basic research and later-stage drug development programs relevant to Alzheimer's disease, related dementias, and cognitive aging. Award amount is up to $600,000 for one year, though multi-year projects will be considered. Letter of interest deadline is May 13.

The Office of Corporate and Foundation Relations has identified the following private funding opportunity:

Alzheimer's Drug Discovery Foundation: 2016 Preclinical Drug Discovery RFP 
http://www.alzdiscovery.org

The Alzheimer's Drug Discovery Foundation is accepting applications that seek to fill the critical translational funding gap between basic research and later stage drug development by funding preclinical drug discovery and biomarker development programs relevant to Alzheimer’s disease, related dementias, and cognitive aging. Funding priorities include drug discovery and biomarker development. Funding mechanisms:

  • Academic program to create and support innovative translational programs in academic medical centers and universities
  • Biotechnology development program supports qualified scientific projects in existing, private, early-stage biotechnology companies. (Typically made as program-related investment)
  • Biotechnology Founders Technology Transfer Program supports academic programs eligible for technology transfer and the start-up of new biotechnology companies.

LOI Deadline: May 13. Invited full proposals due June 3. Application Guidelines for the award. 

The UNC Office of Corporate and Foundation Relations is available to provide assistance in pursuing privately funded opportunities. Email cfr@unc.edu or phone (919) 962-3423. 

Filed under: